Autifony Therapeutics is a technology company.
Autifony Therapeutics has raised $28.0M across 2 funding rounds.
Autifony Therapeutics has raised $28.0M in total across 2 funding rounds.
Autifony Therapeutics has raised $28.0M in total across 2 funding rounds.
Autifony Therapeutics's investors include Soffinova Partners.
Autifony Therapeutics is a clinical-stage UK-based biotechnology company developing novel drugs targeting ion channels, particularly the Kv3 family of potassium channels, to treat rare and serious central nervous system (CNS) disorders.[1][3][5] It serves patients with conditions like Fragile X syndrome, rare epilepsy syndromes (e.g., Myoclonus Epilepsy and Ataxia due to Potassium Channel Mutation or MEAK), schizophrenia, Alzheimer’s disease, and age-related hearing loss, addressing unmet needs where current treatments are limited or ineffective.[1][3][5] The company’s lead programs include AUT00206 (Phase for Fragile X, with FDA Orphan Drug Designation) and AUT00201 (Phase Ib for rare epilepsy), alongside preclinical assets for broader CNS indications, demonstrating steady clinical momentum from its ion channel platform.[3][5]
Autifony Therapeutics was founded in 2011 as a spin-out from GlaxoSmithKline (GSK), with GSK retaining equity, by Charles Large and Giuseppe Alvaro, former Directors at GSK’s Neuroscience Centre of Excellence for Drug Discovery.[1][2] The idea emerged from their expertise in ion channel science, aiming to pioneer treatments for CNS disorders like schizophrenia, Fragile X, Alzheimer’s, and hearing loss—areas with major unmet needs.[1] Early traction came from funding by investors including SV Life Sciences, Touchstone Innovations plc (now UCL Business), Pfizer Venture Investments, and International Biotechnology Trust plc, enabling rapid advancement to clinical-stage programs.[2]
Autifony rides the wave of precision medicine in CNS disorders, where ion channel modulation addresses genetic and neuronal dysfunctions unmet by existing therapies like hearing aids or broad antipsychotics.[1][3][5] Timing aligns with advances in rare disease designations (e.g., FDA Orphan for Fragile X) and growing investment in biotech spin-outs, fueled by market forces like aging populations driving Alzheimer’s/hearing loss prevalence and economic costs of untreated CNS conditions.[1] It influences the ecosystem by validating Kv3 channels as a therapeutic frontier, inspiring similar ion channel research and contributing to the UK biotech hub at Stevenage.[1][6]
Autifony is poised for milestone readouts from AUT00201 Phase Ib and AUT00206 advancement, potentially unlocking partnerships or approvals in rare CNS niches.[3][5] Trends like AI-driven drug discovery and expanded orphan incentives will accelerate its preclinical assets into schizophrenia and hearing loss trials, evolving its role from pioneer to paradigm-shifter in ion channel therapies.[5] As clinical data builds, expect heightened investor interest, amplifying its impact on transforming silent suffering in CNS disorders—echoing its GSK roots in bold neuroscience innovation.[1][2]
Autifony Therapeutics has raised $28.0M across 2 funding rounds. Most recently, it raised $12.0M Series A in July 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2015 | $12.0M Series A | Soffinova Partners | |
| Aug 1, 2011 | $16.0M Seed | Soffinova Partners |